Menu
Search
|

Menu

Close
X

Evolus Inc EOLS.OQ (NASDAQ Stock Exchange Global Market)

14.24 USD
-0.54 (-3.65%)
As of 9:13 PM IST
chart
Previous Close 14.78
Open 14.86
Volume 72,929
3m Avg Volume 126,906
Today’s High 15.30
Today’s Low 14.17
52 Week High 39.50
52 Week Low 6.78
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.432
FY17
-0.056
FY16
-0.335
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

Vikram Malik
Chairman of the Board, Since 2018
Salary: --
Bonus: --
David Moatazedi
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Lauren Silvernail
Chief Financial Officer, Executive Vice President - Corporate Development, Since 2018
Salary: --
Bonus: --
Alejandro Sabad
Vice President - Operations, Since 2018
Salary: --
Bonus: --
Kurt Knab
Vice President of Sales, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

17901 von Karman Ave Ste 150
IRVINE   CA   92614-5245

Phone: +1949.2844555

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

SPONSORED STORIES